Nilofabicin

Research use only, not for human use.

Nilofabicin is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute.

Nilofabicin is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute. (In Vitro):Nilofabicin had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin. Among 203 strains of Staphylococcus aureus, the MICs of Nilofabicin were 0.06 to 1.0 μg/ml, with MIC(50) and MIC(90) values of 0.25 μg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 μg/ml).

——

——

CG-400549 | CG 400549 | CG400549 | CG-0549 | CG 0549 | CG0549 |

GPCR/G Protein

Antibacterial

Prostacyclin receptor

——

——

934628-27-0

340.44

C19H20N2O2S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (293.74 mM)

Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O

——

(-20℃)

With Ice Pack

≥ 2 years